Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan
Journal
Journal of atherosclerosis and thrombosis
Journal Volume
30
Journal Issue
9
Date Issued
2023-09-01
Author(s)
Lin, Po-Lin
Lin, Chao-Feng
Yeh, Hung-I
Chang, Wei-Ting
Charng, Min-Ji
Huang, Po-Hsun
Lin, Chih-Chan
Lin, Tsung-Hsien
Lin, Wei-Wen
Hsieh, I-Chang
Kuo, Feng-Yu
Chen, Ching-Pei
Li, Yi-Heng
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This study aimed to describe the real-world treatment conditions in patients initiating PCSK9 inhibitor in Taiwan.
Subjects
Efficacy; PCSK9 inhibitor; Statin
SDGs
Type
journal article